Statin Therapy in CKD Stage 3: Definitive Recommendation

Primary Recommendation for CKD Stage 3

The American College of Cardiology and European Society of Cardiology recommend initiating a moderate-intensity statin or moderate-intensity statin combined with ezetimibe for patients with CKD stage 3 (eGFR 30-59 mL/min/1.73 m²) not on dialysis, as this provides clear cardiovascular mortality and morbidity benefits, with a Class I/A recommendation from the ESC/EAS guidelines and Class IIa/B-R from the AHA/ACC guidelines 1, 2, 3

For patients aged 40-75 years with LDL-C 70-189 mg/dL and 10-year ASCVD risk ≥7.5%, CKD serves as a risk-enhancing factor that favors statin initiation, according to the American College of Cardiology 4, 3
For patients aged ≥50 years, the American College of Cardiology recommends initiating statin or statin/ezetimibe combination regardless of baseline LDL-C levels 5

The American Journal of Kidney Diseases recommends choosing moderate-intensity statins with appropriate dose adjustments for renal function, with atorvastatin 20 mg daily as the preferred option, which does not require dose adjustment for CKD stage 3 6, 7
The American Journal of Kidney Diseases also recommends rosuvastatin 10 mg daily, with dose adjustment from standard 20 mg for eGFR <60, and pravastatin 40 mg daily as alternative options 7

The American College of Cardiology recommends not initiating statins in patients already on dialysis, with a Class III/B-R recommendation, but it may be reasonable to continue statin therapy if a patient is already taking a statin when dialysis begins, with a Class IIb/C-LD recommendation 4, 3

The American College of Cardiology recommends not withholding statins based solely on eGFR 30-59 mL/min/1.73 m², as this population derives clear benefit, with a recommendation from the Mayo Clinic Proceedings 1, 2, 3
The American College of Cardiology also recommends not using LDL-C targets to guide therapy, instead recommending fixed-dose statin therapy, according to the American Journal of Kidney Diseases and the Journal of the American College of Cardiology 6, 4
The American College of Cardiology recommends not confusing CKD stage 3 with dialysis-dependent CKD, as the evidence and recommendations are completely different for these populations, according to the Journal of the American College of Cardiology 4, 3

The American College of Cardiology recommends considering adding ezetimibe to moderate-intensity statin if the patient has established ASCVD, LDL-C remains elevated despite statin monotherapy, or the patient cannot tolerate higher statin doses, with a recommendation from the Mayo Clinic Proceedings and the American Journal of Kidney Diseases 1, 2, 5, 7

The Kidney International guideline recommends statin therapy for adults aged ≥50 years with CKD, regardless of eGFR level, with statin or statin/ezetimibe combination for those with eGFR <60 ml/min/1.73 m² and statin monotherapy for those with eGFR ≥60 ml/min/1.73 m² (Strong recommendation, 1A) 8, 9, 10, 11
For adults aged 18-49 years with CKD, statin therapy is suggested for those with at least one of the following risk factors: known coronary disease, diabetes mellitus, prior ischemic stroke, or estimated 10-year incidence of coronary death or nonfatal MI >10% (2A) 8, 9, 10

The Kidney International guideline recommends choosing statin regimens that maximize absolute reduction in LDL cholesterol to achieve largest treatment benefits 8, 9
The American Journal of Kidney Diseases guideline provides statin dosing adjustments for specific medications, including atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin 12

The Kidney International guideline suggests considering PCSK-9 inhibitors for CKD patients who have an indication for their use 8, 9
Complement lipid-modifying therapy with a plant-based "Mediterranean-style" diet to further reduce cardiovascular risk 8, 9
Estimate 10-year cardiovascular risk using validated risk tools to guide therapy decisions 8, 9

Statin therapy significantly reduces major atherosclerotic events in CKD patients 13

For patients on dialysis, the evidence for statin initiation is less clear, but current guidelines suggest not initiating statins in dialysis patients but continuing them if already prescribed 14, 15